Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
129 hedge funds and large institutions have $444M invested in Intercept Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 34 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
33% more call options, than puts
Call options by funds: $22.2M | Put options by funds: $16.7M
15% less funds holding
Funds holding: 151 → 129 (-22)
22% less capital invested
Capital invested by funds: $568M → $444M (-$124M)
65% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 34
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.21M |
| 2 |
Two Sigma Investments
New York
|
+$6.35M |
| 3 |
Rockefeller Capital Management
New York
|
+$3.53M |
| 4 |
Two Sigma Advisers
New York
|
+$3.5M |
| 5 |
JP Morgan Chase
New York
|
+$2.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$50.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$12.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.54M |
| 5 |
BlackRock
New York
|
-$2.42M |
ICPT Hedge Fund Activity: Q2 2021 in Review
129 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2021, worth a combined $444M — down 22% from $568M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ICPT and 12 opened new positions — a net loss of 22 holders — while 31 trimmed existing stakes and 53 added.
The largest buyer was Morgan Stanley, adding an estimated $8.21M. The largest seller was First Trust Advisors, cutting an estimated $50.4M.
- 129 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2021, down from 151 in Q1 2021.
- Funds reported $444M of Intercept Pharmaceuticals, Inc. stock for Q2 2021, down 22% quarter-over-quarter.
- 12 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2021 and 34 closed out, a net change of -22 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2021 was Morgan Stanley, an estimated $8.21M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2021 was First Trust Advisors, an estimated $50.4M sold.
Based on aggregated 13F filings for Q2 2021.